Medtronic Navigation Inc

데이터베이스에서 발견된 의료기기 1건 데이터베이스에서 발견된 의료기기 19 건

  • 모델명 / 제조번호(시리얼번호)
    Model: , Affected: model number BI-700-02000
  • 모델명 / 제조번호(시리얼번호)
    Model: , Affected: 9734715 Spinous Process Clamp, Tall, 9734716 Spinous Process Clamp, Short, 9734723 Double Spinous Process Clamp, Tall, 9734724 Double Spinous Process Clamp, Short, 9734715K Spinous Process Clamp, Tall, 9734716K Spinous Process Clamp, Short and 9734723K
  • 모델명 / 제조번호(시리얼번호)
    Model: , Affected: Straight Suction 9733449 EM ENT, Curved Suction 70 9733450 EM ENT, Curved Suction 90 9733451 EM ENT, Suction 9734308 Small Straight AxiEM ENT
  • 모델명 / 제조번호(시리얼번호)
    Model: B1-700-02000, B1-700-00027 & B1-700-00028, Affected: , Software version: Software Version 3.1.x, Software Version 3.2
  • 모델명 / 제조번호(시리얼번호)
    Model: 9735283, 9735283-G02, 9734632, 9734647, 9734648, 9735281, 9735278, 9735282, 9735279, 9735280, Affected: All units
하나 더 14 건 더

유사한 이름을 가진 의료기기 1건 유사한 이름을 가진 의료기기 20 건

데이터에 대해 더 자세히 알아보기 여기

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    NIDFSINVIMA
  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    NIDFSINVIMA
  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    FSSH
  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    LAANSM
하나 더 15 건 더